Scholarlink

Introduction <p>Head and neck atopic dermatitis (AD) is difficult to treat. We evaluated the efficacy of upadacitinib versus placebo in patients with head and neck AD in a post hoc analysis of Measure Up 1 (NCT03569293) and Measure Up 2 (NCT03607422).</p> Methods <p>Patients with head and neck AD (overall and stratified by baseline head and neck Eczema Area and Severity Index [EASI]) received upadacitinib 15&#xa0;mg, upadacitinib 30&#xa0;mg, or placebo. Efficacy assessments included achievement of stringent targets (head and neck EASI ≤ 0.3 [almost clear], EASI 90 [near-complete clearance], EASI 100 [complete clearance], and patient-reported outcomes [PROs]) through week 16.</p> Results <p>At week 16, more patients achieved head and neck EASI ≤ 0.3, EASI 90, and EASI 100 with upadacitinib 15&#xa0;mg (46.8%, 41.9%, 29.1%) and upadacitinib 30&#xa0;mg (58.0%, 56.5%, 42.4%) versus placebo (13.5%, 11.5%, 9.0%), respectively. Similar patterns, including PRO outcomes, were observed across head and neck AD severity subgroups. Total EASI head and neck median percentage reduction from baseline at week 16 was 87.8% for upadacitinib 15&#xa0;mg and 96.3% for upadacitinib 30&#xa0;mg.</p> Conclusions <p>Upadacitinib substantially improved skin and PRO outcomes in patients with head and neck AD, including those with moderate or severe baseline involvement.</p> Trial Registration <p>ClinicalTrials.gov Measure Up 1 (NCT03569293) and Measure Up 2 (NCT03607422).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck Region

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月24日

查看全文
  • Kilian Eyerich,
  • Pedro Mendes-Bastos,
  • Gregor Holzer,
  • Vipul Jain,
  • Norito Katoh,
  • Paula C. Luna,
  • Pablo Coto Segura,
  • Michael Lane,
  • Ayman Grada,
  • Alvaro Moreira,
  • Christopher G. Bunick

摘要

Introduction

Head and neck atopic dermatitis (AD) is difficult to treat. We evaluated the efficacy of upadacitinib versus placebo in patients with head and neck AD in a post hoc analysis of Measure Up 1 (NCT03569293) and Measure Up 2 (NCT03607422).

Methods

Patients with head and neck AD (overall and stratified by baseline head and neck Eczema Area and Severity Index [EASI]) received upadacitinib 15 mg, upadacitinib 30 mg, or placebo. Efficacy assessments included achievement of stringent targets (head and neck EASI ≤ 0.3 [almost clear], EASI 90 [near-complete clearance], EASI 100 [complete clearance], and patient-reported outcomes [PROs]) through week 16.

Results

At week 16, more patients achieved head and neck EASI ≤ 0.3, EASI 90, and EASI 100 with upadacitinib 15 mg (46.8%, 41.9%, 29.1%) and upadacitinib 30 mg (58.0%, 56.5%, 42.4%) versus placebo (13.5%, 11.5%, 9.0%), respectively. Similar patterns, including PRO outcomes, were observed across head and neck AD severity subgroups. Total EASI head and neck median percentage reduction from baseline at week 16 was 87.8% for upadacitinib 15 mg and 96.3% for upadacitinib 30 mg.

Conclusions

Upadacitinib substantially improved skin and PRO outcomes in patients with head and neck AD, including those with moderate or severe baseline involvement.

Trial Registration

ClinicalTrials.gov Measure Up 1 (NCT03569293) and Measure Up 2 (NCT03607422).